Recruiting NCT07433400
Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Ph Positive ALL. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Retrospective Study of the Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
Overview
The objective of this retrospective study is to examine the outcome of patients who relapse with Ph+ ALL and to potentially identify response profiles in order toadvance the treatment regimens that can be offered.
Primary outcome measures
- Long term survival [Time frame: 5 years]
Secondary outcome measures (8)
- 10 year-survival [Time frame: 10 years]
- Molecular response (BCR::ABL1 ratio) [Time frame: At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse]
- Hematologic response [Time frame: At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse]
- Death date [Time frame: Up to 10 years]
- Cause of death [Time frame: Up to 10 years]
- Treatment characteristics (treatment name) [Time frame: At day 1 of each new treatment of relapse]
- Treatment characteristics (treatment dates) [Time frame: At day 1 and at the end of each line of treatment of relapse]
- Treatment characteristics (dose) [Time frame: At day 1 of each new treatment of relapse]
Eligibility criteria
Inclusion criteria
- Age >= 18
- Relapse or refractory Ph1 ALL
Exclusion criteria
- none
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- GRAALL — Pierre-Bénite
Identifiers
NCT: NCT07433400 · EVOLALPh1